

Ref	Study	n pts	Nodal Resection	RT dose	Concurrent chemotherapy/ Chemotherapy arm	Completion rate	Overall survival	Locoregional Control	Disease free survival	Grade 3-4 toxicity	
										Haematologic	Digestive
	Bamias A, 2010	72 CRT 71 CT	D1/D2	45 Gy	DP DP	69% 87%	3-yr OS: CRT 57% vs CT 61%% (p=NS)	Overall LRRFS : CRT 95% vs CT 90% (NS)	3-yr DFS CRT 48% vs CT 51% (p = NS)	30% 23%	8% 7%
	Kwon H, 2010	31 CRT 30 CT	D2	45 Gy	Capecitabin* 5FU+P	74.2% 73.3%	5-yr OS: CRT 70.1% vs CT 70% (NS)	Overall LRRFS : CRT 87.1% vs CT 76.7% (NS)	5-yr DFS CRT 76.7% vs CT 59.1% (p = NS)	61.3% 33.4%	12.9% 13.3%
	Yu C, 2012	34 CRT 34 CT	D1/D2	45 Gy	LV-5FU LV-5FU	89% 100%	3-yr OS: CRT 67.7% vs CT 44.1%% (p=0.037)	NA	3-yr DFS CRT 55.8% vs CT 29.4% (p = 0.029)	50% 29.3%	23.2% 13.8%
	Zhu W, 2012	186 CRT 165 CT	D2	45 Gy	LV-5FU LV-5FU	N/A	5-yr OS: CRT 48.4% vs CT 41.8% (NS)	5-yr LRRFS : CRT 84.4% vs CT 75.8%(p=0.04)	5-yr DFS CRT 45.2% vs CT 35.8% (p = 0.021)	7.5% 7.3%	13.4% 0%
	Kim T, 2012	46 CRT 44 CT	D2	45 Gy	LV-5FU LV-5FU	87% 93%	5-yr OS: CRT 65.2% vs CT 54.6% (NS)	5-yr LRRFS : CRT 84.4% vs CT 62.7%(p=0.035)	5-yr DFS CRT 60.9% vs CT 50% (NS)	19.6% 25%	17.4% 11.4%
	ARTIST	230 CRT 228 CT	D2	45 Gy	Capecitabin* Capecitabin+P	75.4% 81.7%	5-yr OS: CRT 73% vs CT 75% (NS)	NA	5-yr DFS CRT 78.2% vs CT 74.2% (NS)	49.7% 42.4%	17.2% 19%
	ARTIST 2	183 CRT 181 CT1 182 CT2	D2	45 Gy	S* SOX S	83% 85% 71%	NA	NA	3-yr DFS CRT 72.8% vs CT1 69.6% (NS)	10% 14% 6%	2% 9% 10%
	CRITICS	395 CRT 393 CT	D1/D2	45 Gy	Capecitabin+P* EOX/ECF	50% 46%	5-yr OS: CRT 40% vs CT 42% (NS)	NA	5-yr DFS CRT 38% vs CT 39% (NS)	12% 40%	41% 41%

Table 1 : Summary of prospective randomized trials investigating adjuvant chemoradiotherapy (CRT) versus perioperative chemotherapy (CT). Abbreviations: DP: Docetaxel-Cis/Carboplatin; 5FU+P: 5-Fluorouracil+Cisplatin; S: S1; SOX: S1+Oxaliplatin; EOX: Epirubicin Oxaliplatin Xeloda; ECF: Epirubicin Cisplatin 5-Fluorouracil; LV-5FU: Leucovorin+5-Fluorouracil; OS: Overall Survival; LRRFS: Locoregional Relapse-Free Survival; DFS: Disease-Free Survival; *: induction/adjuvant chemotherapy; NS: Non Significant; NA: Not Ascertained.